Envafolimab
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Target | PD-L1 |
| Clinical data | |
| Drug class | Antineoplastic agent |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy.[1] It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours.[2] Envafolimab (KN035) has obtained the U.S. FDA's orphan drug designation for advanced biliary tract cancer.
References
[edit]- ^ "Envafolimab - Alphamab Oncology/Ascletis/3D Medicine". AdisInsight. Springer Nature Switzerland AG.
- ^ Markham A (February 2022). "Envafolimab: First Approval". Drugs. 82 (2): 235–240. doi:10.1007/s40265-022-01671-w. PMID 35122636. S2CID 246534311.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |